Genetics and Genomic Medicine Center - GGMC

03/01/2026

𝐄𝐱𝐭𝐞𝐧𝐝𝐢𝐧𝐠 𝐨𝐮𝐫 𝐰𝐚𝐫𝐦𝐞𝐬𝐭 𝐰𝐢𝐬𝐡𝐞𝐬 𝐭𝐨 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞 𝐟𝐨𝐫 𝐚 𝐡𝐚𝐩𝐩𝐲 & 𝐩𝐫𝐨𝐬𝐩𝐞𝐫𝐨𝐮𝐬 𝐍𝐞𝐰 𝐘𝐞𝐚𝐫 𝟐𝟎𝟐𝟔 🌟

In the year ahead, we move forward with a renewed commitment to building an even stronger foundation through enhanced expertise and experience. We continue to expand our offerings by introducing modern and reliable new tests, improved services, and innovative initiatives.

With your trust, support, and continued cooperation, we strive to further strengthen our position as one of the country’s leading healthcare service providers.

Thank you for being an integral part of this journey.
May the New Year bring good health, success, and hope to all. ✨
🧬

📞 NeuroGen Healthcare
📱 Phone: 01787662575
📍 Eastern Dolan, Level-4 & 9 (GGMC)
152/2-H, Bir Uttam Kazi Nuruzzaman Sarak
West Panthapath, Green Road
Dhaka-1205, Bangladesh

29/12/2025

🔬 𝐆𝐆𝐌𝐂 𝐂𝐚𝐬𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
𝐃𝐎𝐏𝐀-𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐯𝐞 𝐃𝐲𝐬𝐭𝐨𝐧𝐢𝐚 — 𝐀 𝐓𝐫𝐞𝐚𝐭𝐚𝐛𝐥𝐞 𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐔𝐧𝐦𝐚𝐬𝐤𝐞𝐝 𝐛𝐲 𝐖𝐄𝐒

A 12.1-year-old boy, born to healthy consanguineous parents, was referred for genetic testing at NeuroGen Healthcare’s genetic lab Genetics and Genomic Medicine Center - GGMC.

Symptoms began around 2 years of age, and the child was 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐥𝐚𝐛𝐞𝐥𝐞𝐝 𝐚𝐬 𝐃𝐌𝐃 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝟐–𝟓 𝐲𝐞𝐚𝐫𝐬. He exhibited severe developmental delay, inability to walk or speak, and generalized spasticity.

👩‍⚕️ 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐟𝐞𝐫𝐫𝐚𝐥:
The patient was referred for 𝐖𝐡𝐨𝐥𝐞 𝐄𝐱𝐨𝐦𝐞 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 (𝐖𝐄𝐒) 𝐛𝐲 𝐀𝐬𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐃𝐫. 𝐍𝐮𝐬𝐫𝐚𝐭 𝐒𝐡𝐚𝐦𝐬, NeuroGen Healthcare.

🧬 𝐖𝐄𝐒 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬:
👉 A homozygous missense variant was identified in the 𝑮𝑪𝑯1 gene
👉 Pathogenic biallelic (recessive) variants in 𝑮𝑪𝑯1 are associated with
𝐃𝐎𝐏𝐀-𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐯𝐞 𝐃𝐲𝐬𝐭𝐨𝐧𝐢𝐚 (OMIM #128230)

🧠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐂𝐨𝐫𝐫𝐞𝐥𝐚𝐭𝐢𝐨𝐧:
Disruption of the 𝑮𝑪𝑯1 gene impairs dopamine biosynthesis, leading to movement disorders that are often misdiagnosed but potentially highly treatable.

💊 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 & 𝐅𝐨𝐥𝐥𝐨𝐰-𝐮𝐩:
Following confirmation of the genetic diagnosis, L-Dopa therapy was initiated by Dr. Nusrat Shams.

𝐀𝐟𝐭𝐞𝐫 𝟑 𝐦𝐨𝐧𝐭𝐡𝐬 𝐨𝐟 𝐟𝐨𝐥𝐥𝐨𝐰-𝐮𝐩, 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐰𝐚𝐬 𝐨𝐛𝐬𝐞𝐫𝐯𝐞𝐝:
👉 The child is now able to talk
👉 Shows purposeful movement of body parts
👉 Can move independently by crawling from one place to another
👉 Has started physiotherapy at NeuroGen Healthcare

🧠 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐍𝐨𝐭𝐞:
👉DOPA-responsive dystonia is a rare but highly treatable genetic movement disorder.
👉Delayed or missed diagnosis may result in years of unnecessary disability, whereas timely WES-based diagnosis enables targeted therapy and dramatic improvement in quality of life.

22/12/2025

𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐝𝐨𝐞𝐬 𝐧𝐨𝐭 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐭𝐡𝐞 𝐠𝐮𝐭 𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐨𝐦𝐞 𝐚𝐬 𝐚 𝐜𝐚𝐮𝐬𝐞 𝐨𝐟 𝐚𝐮𝐭𝐢𝐬𝐦 👧🧠🔬🦠

🔍Large-scale analyses show that many reported microbial differences disappear after accounting for diet and family-related factors.
🍽️This suggests autism may influence dietary patterns, not the other way around.
⚠️Many earlier studies suffered from small sample sizes and weak statistical methods.
🧬Autism is strongly genetic and neurodevelopmental in origin.
🎯Research efforts should focus on brain biology and genetics rather than unproven microbiome theories.



Learn more: https://neurosciencenews.com/asd-microbiome-neuroscience-29933/

10/12/2025

🧬𝐇𝐨𝐫𝐢𝐳𝐨𝐧 𝐂𝐚𝐬𝐞 𝐒𝐞𝐫𝐢𝐞𝐬 | 𝐂𝐚𝐬𝐞 𝟎𝟏: 𝐅𝐨𝐜𝐚𝐥 𝐄𝐩𝐢𝐥𝐞𝐩𝐬𝐲 & 𝐍𝐞𝐮𝐫𝐨𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐚𝐥 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬

Sharing the first episode of the 𝑯𝒐𝒓𝒊𝒛𝒐𝒏 𝑪𝒂𝒔𝒆 𝑺𝒆𝒓𝒊𝒆𝒔, hosted by 𝐃𝐫. 𝐌𝐨𝐡𝐚𝐦𝐦𝐚𝐝 𝐔𝐝𝐝𝐢𝐧, 𝐅𝐨𝐮𝐧𝐝𝐞𝐫 & 𝐂𝐄𝐎 𝐨𝐟 𝐆𝐞𝐧𝐨𝐦𝐞𝐀𝐫𝐜 and Chief Scientific Advisor at 𝐍𝐞𝐮𝐫𝐨𝐆𝐞𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 & Genetics and Genomic Medicine Center - GGMC

The 𝐆𝐞𝐧𝐨𝐦𝐞𝐀𝐫𝐜 𝐇𝐨𝐫𝐢𝐳𝐨𝐧® 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 by Dr. Mohammad Uddin himself, is now being effectively utilized at GGMC for accurate and efficient genetic diagnosis.

In this episode, Dr. Hosneara Akter, Director of GGMC, discusses a complex clinical case involving 𝑲𝑪𝑵𝑯1 𝐚𝐧𝐝 𝑮6𝑷𝑫 𝐯𝐚𝐫𝐢𝐚𝐧𝐭𝐬 𝐢𝐧 𝐚 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐟𝐨𝐜𝐚𝐥 𝐞𝐩𝐢𝐥𝐞𝐩𝐬𝐲.

Hope to see many more such impactful case series showcasing advanced genomic applications in real clinical settings.

🔗 Watch the full episode: https://www.youtube.com/watch?v=DYQR_OwXCvI

06/12/2025

► 𝐆𝐫𝐚𝐩𝐡𝐢𝐜 𝐃𝐞𝐬𝐢𝐠𝐧 & 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠 𝐒𝐩𝐞𝐜𝐢𝐚𝐥𝐢𝐬𝐭

📍 Location: Eastern Dolan, Level - 4 ( 3rd Floor ), 152/2-H, Bir Uttam Kazi Nuruzzaman Sarak, West Panthapath, Green Road, Dhaka - 1205, Bangladesh

🧬 Join the frontier of NeuroGen Healthcare Ltd
Our company is part of the fast-growing health tech company transforming the landscape of rare disease and cancer diagnosis using AI-powered genomic insights. We are looking for a creative and driven Digital Marketing & Graphics Design Specialist to help us communicate our innovations to the world.

► Job Responsibilities :

• Design engaging visual content: images, infographics, short-form videos, and presentations that reflect our mission and platform capabilities.
• Develop brand-consistent graphics for website, email, and social media.
• Translate complex genomic and AI concepts into simple, visually appealing graphics.
• Support internal teams with creative materials (brochures, decks, banners, etc.).
• Plan and execute campaigns across LinkedIn, Twitter/X, Instagram, Google Ads, and YouTube.
• Manage website content, newsletters, and social channels with a consistent brand voice.
• Create copy and visuals for ads, posts, and client communications.
• Reach out to potential clients and collaborators with clear, concise, and compelling messaging.

► Requirements :

• Bachelor’s degree in Marketing, Design, Communication, or a related field.
• Strong visual storytelling and design skills (Adobe Creative Suite, Canva, Figma or similar).
• Experience in creating short-form videos, reels, motion graphics and image-based marketing content.
• Excellent written and spoken English; able to explain technical ideas clearly to a broad audience.
• Comfortable reaching out to clients or researchers to explain platform and solutions.
• Passionate about science, healthcare, or technology.
• The ability to handle dozens of opportunities in parallel.

► Starting Salary: 20K

► To Apply:

Say us on why you’re the right person for the job: send your resume and the reasons why we should hire you to career@neurogenbd.com

30/11/2025

𝐃𝐞𝐝𝐢𝐜𝐚𝐭𝐞𝐝 𝑩𝑹𝑪𝑨1 & 𝑩𝑹𝑪𝑨2 𝐆𝐞𝐧𝐞 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐏𝐚𝐧𝐞𝐥 𝐟𝐨𝐫 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗶𝘀𝗸 🎗️ 🩸 🧬

🎗️𝑩𝑹𝑪𝑨1 (BReast CAncer gene 1) এবং 𝑩𝑹𝑪𝑨2 (BReast CAncer gene 2) DNA repair-এর জন্য গুরুত্বপূর্ণ gene। এই gene-এ ক্ষতিকর mutation হলে 𝐇𝐞𝐫𝐞𝐝𝐢𝐭𝐚𝐫𝐲 𝐁𝐫𝐞𝐚𝐬𝐭 𝐚𝐧𝐝 𝐎𝐯𝐚𝐫𝐢𝐚𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 (𝐇𝐁𝐎𝐂) সহ আরও অনেক রোগের ঝুঁকি বেড়ে যায়।

🎗️𝑩𝑹𝑪𝑨1/𝑩𝑹𝑪𝑨2 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐫𝐫𝐢𝐞𝐫𝐬-দের ক্ষেত্রে breast cancer হওয়ার lifetime risk প্রায় ৮৪% পর্যন্ত এবং ovarian cancer-এর ঝুঁকি ৩৯% পর্যন্ত হতে পারে। (PMID: 25224030)

🔴কেন এই টেস্ট দরকার?
𝑩𝑹𝑪𝑨1/𝑩𝑹𝑪𝑨2 gene-এ mutation থাকলে—
🧍‍♀️নারীদের ক্ষেত্রে breast ও ovarian cancer-এর উচ্চ ঝুঁকি থাকে
🧍‍♂️পুরুষদের ক্ষেত্রে prostate, pancreatic ও male breast cancer-এর সম্ভাবনা বাড়ে
🩺চিকিৎসা নির্ধারণে গুরুত্বপূর্ণ ভূমিকা রাখে (যেমন PARP inhibitors ব্যবহারের সুযোগ)

🔴কারা এই টেস্ট বিবেচনা করবেন?
👉যাদের কম বয়সে breast/ovarian cancer ধরা পড়েছে
👉যেসব পরিবারে একাধিক cancer (breast, ovarian, prostate, pancreatic) রয়েছে
👉পরিবারে 𝐁𝐑𝐂𝐀 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧 নিশ্চিত হলে অন্য সদস্যরা (cascade testing)

🔴টেস্টের উপকারিতা:
👉Personal screening ও prevention strategy নির্ধারণে সহায়ক
👉ঝুঁকি কমাতে surgery-এর সিদ্ধান্তে দিকনির্দেশনা দেয়
👉Targeted therapy নির্বাচনে সহায়তা করে
👉পরিবারে অন্যদের জন্য testing ও genetic counseling সহজ হয়

► GGMC-তে প্রতিটি ধাপ নিখুঁত যত্ন ও দক্ষতার সাথে সম্পন্ন করা হয় — sample preparation থেকে শুরু করে sequencing, data analysis এবং final reporting পর্যন্ত।
📊 ১০ বছরের অভিজ্ঞতায় GGMC ইতোমধ্যে ১০০০+ জেনেটিক টেস্ট এবং ৮০০+ বিরল রোগ নির্ণয় সম্পন্ন করেছে, প্রতিটি ধাপে নিশ্চিত করেছে নির্ভরযোগ্য ফলাফল।

📞 NeuroGen Healthcare
🌐 www.neurogenbd.com
📱 Phone: 01787662575
📍 Eastern Dolan, Level - 4,
152/2-H, Bir Uttam Kazi Nuruzzaman Sarak,
West Panthapath, Green Road, Dhaka - 1205, Bangladesh

26/11/2025

𝐒𝐩𝐢𝐧𝐚𝐥 𝐌𝐮𝐬𝐜𝐮𝐥𝐚𝐫 𝐀𝐭𝐫𝐨𝐩𝐡𝐲 (𝐒𝐌𝐀) – 𝗡𝗲𝘄 𝗗𝗿𝘂𝗴 𝗨𝗽𝗱𝗮𝘁𝗲! 🧬

🔹 Itvisma (onasemnogene abeparvovec-brve) is a one-time gene replacement therapy recently approved by the U.S. FDA for the rare genetic disorder Spinal Muscular Atrophy (SMA). It can be administered to children above 2 years, adolescents, and adults who carry SMN1 gene mutations.

🔹 𝐊𝐞𝐲 𝐅𝐚𝐜𝐭𝐬 𝐀𝐛𝐨𝐮𝐭 𝐈𝐭𝐯𝐢𝐬𝐦𝐚:
🧬 Itvisma is a one-time gene replacement therapy indicated for individuals (2 years and older) with SMA caused by pathogenic mutations in the SMN1 gene.

💉 It is an AAV (adeno-associated virus)–based gene therapy.
It is administered as a single-dose treatment, meaning patients do not require repeated dosing.

🧠 The dosing method is intrathecal injection — meaning it is delivered directly into the spinal fluid, allowing the therapy to reach motor neurons and deliver the SMN1 gene effectively.

🔧 The therapy works by replacing the faulty SMN1 gene, enabling neurons to produce adequate SMN protein, helping to slow motor neuron degeneration and reduce muscle weakness.

🌟 In the future, we will surely witness more precision medicines like Itvisma, offering effective treatment options for rare genetic diseases.

Sources:
https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy #:~:text=The%20U.S.%20Food%20and%20Drug,neuron%201%20(SMN1)%20gene.

https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma

https://www.curesma.org/novartis-receives-fda-approval-of-itvisma-for-the-treatment-of-sma/

23/11/2025

𝟏𝟗𝐭𝐡 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓, 𝐍𝐞𝐮𝐫𝐨𝐆𝐞𝐧 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬 𝐌𝐞𝐞𝐭𝐮𝐩 (𝟐𝐧𝐝 𝐒𝐞𝐬𝐬𝐢𝐨𝐧)! 👩‍🔬👨‍⚕️

22/11/2025

𝐍𝐞𝐮𝐫𝐨𝐆𝐞𝐧 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬 𝐌𝐞𝐞𝐭𝐮𝐩 𝟏𝐬𝐭 𝐬𝐞𝐬𝐬𝐢𝐨𝐧 𝐡𝐞𝐥𝐝 𝐨𝐧 𝟏𝟔𝐭𝐡 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟓!

19/11/2025

🧬𝑮𝒆𝒏𝒆𝒕𝒊𝒄 𝑪𝒐𝒖𝒏𝒔𝒆𝒍𝒐𝒓 𝑨𝒑𝒑𝒓𝒆𝒄𝒊𝒂𝒕𝒊𝒐𝒏 𝑫𝒂𝒚 2025🧬👩‍⚕️
𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 is recognized as Genetic Counselor Appreciation / Awareness Month.
We express our heartfelt respect to all Genetic Counselors 👩‍⚕️🧬👨‍⚕️ across the world — who stand beside patients and their families, raise awareness about genetic conditions, and play a vital role in guiding them toward informed medical decisions.

𝐒𝐢𝐧𝐜𝐞 𝟐𝟎𝟏𝟕, 𝐍𝐞𝐮𝐫𝐨𝐆𝐞𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐢𝐧 𝐁𝐚𝐧𝐠𝐥𝐚𝐝𝐞𝐬𝐡 𝐭𝐨 𝐢𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐞 𝐆𝐞𝐧𝐞𝐭𝐢𝐜 𝐂𝐨𝐮𝐧𝐬𝐞𝐥𝐢𝐧𝐠 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬, 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐭𝐡𝐢𝐬 𝐬𝐞𝐫𝐯𝐢𝐜𝐞 𝐰𝐡𝐢𝐥𝐞 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬.

We believe that in the coming years, Genetic Counseling will become more widespread across Bangladesh, ensuring greater support and benefits for families. 💙
📌 NeuroGen Healthcare
🌐 www.neurogenbd.com

📞 01787662575
🏥 Address:
NeuroGen Healthcare
Eastern Dolan, Level – 4
152/2-H, Bir Uttam Kazi Nuruzzaman Sarak
West Panthapath, Green Road
Dhaka – 1205, Bangladesh

08/11/2025

🧬𝐉𝐚𝐦𝐞𝐬 𝐃. 𝐖𝐚𝐭𝐬𝐨𝐧, 𝐭𝐡𝐞 𝐃𝐍𝐀 𝐏𝐢𝐨𝐧𝐞𝐞𝐫 𝐖𝐡𝐨 𝐂𝐨-𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐈𝐭𝐬 𝐃𝐨𝐮𝐛𝐥𝐞-𝐇𝐞𝐥𝐢𝐱 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞, 𝐏𝐚𝐬𝐬𝐞𝐬 𝐀𝐰𝐚𝐲 𝐚𝐭 𝟗𝟕

The world of genetics has lost one of its greatest pioneers — 𝗗𝗿. 𝗝𝗮𝗺𝗲𝘀 𝗗. 𝗪𝗮𝘁𝘀𝗼𝗻 (April 6, 1928 – November 6, 2025), who passed away at the age of 97.

As a 𝐜𝐨-𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐝𝐨𝐮𝐛𝐥𝐞-𝐡𝐞𝐥𝐢𝐱 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐨𝐟 𝐃𝐍𝐀 𝐢𝐧 𝟏𝟗𝟓𝟑, 𝐃𝐫. 𝐖𝐚𝐭𝐬𝐨𝐧’𝐬 𝐰𝐨𝐫𝐤 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐞𝐝 𝐭𝐡𝐞 𝐯𝐞𝐫𝐲 𝐟𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐩𝐚𝐯𝐞𝐝 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐟𝐨𝐫 𝐦𝐨𝐝𝐞𝐫𝐧 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬, 𝐚𝐧𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞.

His discovery opened the door to understanding how DNA behaves, how genetic variations are linked to different disorders, and how that knowledge can ultimately lead to targeted treatments and new drug discoveries. The remarkable progress we see today in genomics and precision medicine traces back to this groundbreaking achievement.

We extend our deepest respect and gratitude to Dr. Watson for his monumental contribution to science and humanity.

May his legacy continue to inspire future generations of geneticists and clinicians around the world.

Learn more:
https://www.npr.org/2025/11/07/nx-s1-5144654/james-watson-dna-double-helix-dies

James Watson, who co-discovered the structure of DNA has died at age 97. He was a scientific superstar until he made racist remarks that made him an outcast.

19/10/2025

🧬𝐌𝐞𝐧 𝐰𝐢𝐭𝐡 𝐁𝐑𝐂𝐀𝟏 𝐚𝐧𝐝 𝐁𝐑𝐂𝐀𝟐 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐒𝐡𝐨𝐮𝐥𝐝 𝐑𝐞𝐜𝐞𝐢𝐯𝐞 𝐀𝐧𝐧𝐮𝐚𝐥 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠!
In our country, 𝑩𝑹𝑪𝑨1 𝒂𝒏𝒅 𝑩𝑹𝑪𝑨2 gene testing is mostly done for women, as these genes are strongly associated with breast and ovarian cancer risk. However, many may not know that men can also carry these genetic faults. While male breast cancer is rare, mutations in 𝑩𝑹𝑪𝑨1 𝒂𝒏𝒅 𝑩𝑹𝑪𝑨2 can greatly increase the risk of prostate cancer in men.

A recent international study presented at the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐒𝐨𝐜𝐢𝐞𝐭𝐲 𝐟𝐨𝐫 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 (𝐄𝐒𝐌𝐎) 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟓 showed that men with 𝑩𝑹𝑪𝑨1 or 𝑩𝑹𝑪𝑨2 mutations should undergo annual 𝐏𝐒𝐀 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 to detect prostate cancer early—when it is most treatable.

🎗️ This October, let’s raise awareness about all types of cancer—for both men and women—and encourage timely testing and prevention.

Learn more:
https://www.icr.ac.uk/about-us/icr-news/detail/men-with-brca1-and-brca2-gene-mutations-should-get-annual-prostate-cancer-screening

𝑭𝒐𝒓 𝒅𝒆𝒕𝒂𝒊𝒍𝒔 𝒂𝒃𝒐𝒖𝒕 𝒐𝒖𝒓 𝑪𝒂𝒏𝒄𝒆𝒓 𝑮𝒆𝒏𝒆 𝑷𝒂𝒏𝒆𝒍, 𝑩𝑹𝑪𝑨1 & 𝑩𝑹𝑪𝑨2 𝑮𝒆𝒏𝒆𝒕𝒊𝒄 𝑻𝒆𝒔𝒕𝒊𝒏𝒈 𝑷𝒂𝒏𝒆𝒍, 𝒐𝒓 𝒂𝒏𝒚 𝑮𝒆𝒏𝒆𝒕𝒊𝒄 𝑺𝒄𝒓𝒆𝒆𝒏𝒊𝒏𝒈, 𝒗𝒊𝒔𝒊𝒕 𝒐𝒖𝒓 𝑮𝒆𝒏𝒆𝒕𝒊𝒄 𝑪𝒐𝒖𝒏𝒔𝒆𝒍𝒊𝒏𝒈 𝑺𝒆𝒔𝒔𝒊𝒐𝒏.

𝗡𝗲𝘂𝗿𝗼𝗚𝗲𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲
🌐 www.neurogenbd.com
📞 01787662575
📍 Eastern Dolan, Level - 4, 152/2-H, Bir Uttam Kazi Nuruzzaman Sarak, West Panthapath (Former Green Road), Dhaka - 1205, Bangladesh